alexa Cancer Suicide Gene Therapy | OMICS International
ISSN: 2157-7412
Journal of Genetic Syndromes & Gene Therapy

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Cancer Suicide Gene Therapy

Marek Malecki*

University of Wisconsin, Madison, WI, USA and Phoenix Biomolecular Engineering Foundation, San Francisco, CA, USA

Corresponding Author:
Marek Malecki
President, Genetic and Biomolecular Engineering
PBMEF, San Francisco, CA, USA
Tel: 4157134370
E-mail: [email protected]

Received October 19, 2012; Accepted October 19, 2012; Published October 22, 2012

Citation: Malecki M (2012) Frontiers in Suicide Gene Therapy of Cancer. J Genet Syndr Gene Ther 3:e114. doi: 10.4172/2157-7412.1000e114

Copyright: © 2012 Malecki M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Genetic Syndromes & Gene Therapy

The NCI predicts that 1,638,910 men and women will be diagnosed with cancer in the USA in 2012. Nearly 577,190 patients will die of cancer of all sites that year. Patients undergoing current systemic therapies will suffer multiple side effects from nausea to infertility. Potential parents, when diagnosed with cancer, will have to deposit oocytes and sperms prior to starting systemic radiation or chemotherapy for the future genetic testing and in vitro fertilization, while avoiding risks of mutations in their germ cells. Otherwise, children, of parents treated with systemic therapies, will be at high risk of developing genetic disorders. [1,2]

Cancer is a genetic disease; therefore rapid progress in genomics and proteomics is critical for identifying the molecular causes of these diseases. In general, therapeutics aimed to cure patients diagnosed with cancer, should have no iatrogenic effects. As unfortunately, it is not the case with the current systemic therapies, the demand for the side-effects- free therapy is enormous. One of the most promising therapeutic strategies in this regard is cancer suicide gene therapy (CSGT).

The therapeutic success is primarily contingent upon precision in delivery of the therapeutic transgenes to the cancer cells only. This is addressed by discovering and targeting unique or / and over-expressed biomarkers displayed on the cancer cells and cancer stem cells. Specificity of cancer therapeutic effects is further enhanced by designing the DNA constructs, which put the therapeutic genes under the control of the cancer cell specific promoters. The delivery of the suicidal genes to the cancer cells involves viral, as well as synthetic vectors, which are guided by cancer specific antibodies and ligands. The delivery options also include engineered stem cells with tropisms towards cancers. Main mechanisms, inducing cancer cell death, include transgenic expression of thymidine kinases, cytosine deaminases, intracellular antibodies, telomeraseses, caspases, and DNases. Precautions are undertaken to eliminate the risks associated with transgenesis.

In the forthcoming issue of the Journal of Genetic Syndromes and Gene Therapy, the experts in cancer suicide gene therapy will share their experience from research and clinical trials, as well as plans for the future endeavors.


This work was supported by the funds from the NIH (RR000570), the NSF (9420056, 9522771, 9902020, 0094016), and the PBMEF, granted to Marek Malecki MD PhD, Principal Investigator.

Conflict of Interest

The author declares no conflict of interest.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 5th International Conference on Human Genetics and Genetic Disorders September 21-22,2018 Philadelphia, USA Theme: Sharing Discoveries of the Future Human Genome
    September 21-22,2018 Philadelphia, USA

Article Usage

  • Total views: 11863
  • [From(publication date):
    September-2012 - Jul 22, 2018]
  • Breakdown by view type
  • HTML page views : 8070
  • PDF downloads : 3793

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7